Advertisement

ADVERTISEMENT

mantle cell lymphoma

From the Field
Real-World Characteristics and Outcomes of Patients With Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Treated With First-Line Bendamustine + Rituximab
04/20/2022
Rouslan Kotchetkov, MD, PhD
David Susman
Erica DiMaria, MD
Lauren Gerard, MD
Derek Nay, MD
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues...
04/20/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of KTE-X19 vs Standard of Care for Relapsed/Refractory MCL
03/16/2021
03/16/2021
Journal of Clinical Pathways
News
Real-World Practice Patterns, Comorbidities in Medicare Patients With MCL
01/21/2021
01/21/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness Comparison of BTK Inhibitors for MCL
12/09/2020
12/09/2020
Journal of Clinical Pathways
News
Optimal Real-World Immunochemotherapy Regimen for Patients With MCL
06/25/2020
A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...
A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...
A...
06/25/2020
Journal of Clinical Pathways
News
Predicting Clinical Outcomes of Patients With High-Risk MCL
06/18/2020
Patients with high-risk mantle cell lymphoma (MCL) biology—defined by blastoid variance, Ki-67 greater than 30%, or high p53 immunohistochemistry expression—are more likely to experience shorter failure-free and...
Patients with high-risk mantle cell lymphoma (MCL) biology—defined by blastoid variance, Ki-67 greater than 30%, or high p53 immunohistochemistry expression—are more likely to experience shorter failure-free and...
...
06/18/2020
Journal of Clinical Pathways
News
Modified MIPI Scoring System Provides Clinical, Biological Prognostic Indicators for MCL
06/11/2020
At the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020), researchers from the North American Mantle Cell Lymphoma (MCL) Consortium offered clinical, biological, and genomic markers that...
At the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020), researchers from the North American Mantle Cell Lymphoma (MCL) Consortium offered clinical, biological, and genomic markers that...
At the...
06/11/2020
Journal of Clinical Pathways
News
Practice Patterns, Predictors of Survival for Older Patients With MCL
05/27/2020
A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...
A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...
A new...
05/27/2020
Journal of Clinical Pathways
News
Real-World HRU, Costs in Patients With MCL Treated With Drug Combo vs Chemoimmunotherapy
05/20/2020
Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...
Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...
...
05/20/2020
Journal of Clinical Pathways
Research in Review
Patients With MCL and a Specific Mutation in Need of Alternative Frontline Therapies
08/21/2017
JCP Editors
Patients with mantle cell lymphoma (MCL) should be stratified based on the status of a specific mutation and considered for alternative first-line therapy, according to a new study published in Blood (online August...
Patients with mantle cell lymphoma (MCL) should be stratified based on the status of a specific mutation and considered for alternative first-line therapy, according to a new study published in Blood (online August...
...
08/21/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use